Advancing multiplex base editing into the clinic

Cell & Gene Therapy Insights 2023; 9(9), 1249–1254

DOI: 10.18609/cgti.2023.162

Published: 10 November 2023
Gopi Shanker

David McCall, Senior Editor, BioInsights, speaks to Gopi Shanker, Chief Scientific Officer, Beam Therapeutics, about the company’s mission to realize the full potential of base editing for patient treatment. They discuss the stand-out advantages of base editing, as well as the current state of the art in the area of multiplex gene editing.